FMP
NASDAQ
8.37 USD
0 (0%)
Dr. Roger D. Tung Ph.D.
Healthcare
Biotechnology
https://www.concertpharma.com
NASDAQ
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
0001367920
US2060221056
206022105
65 Hayden Avenue
781 860 0045
US
64
Feb 13, 2014